Forkhead-associated (FHA) domains are modules that bind to phosphothreonine (pThr) residues in signaling cascades. The FHA-containing mycobacterial protein GarA is a central element of a phosphorylation-dependent signaling pathway that redirects metabolic flux in response to amino acid starvation or cell growth requirements. GarA acts as a phosphorylation-dependent ON/OFF molecular switch. In its nonphosphorylated ON state, the GarA FHA domain engages in phosphorylation-independent interactions with various metabolic enzymes that orchestrate nitrogen flow, such as 2-oxoglutarate decarboxylase (KGD). However, phosphorylation at the GarA N-terminal region by the protein kinase PknB or PknG triggers autoinhibition through the intramolecular association of the N-terminal domain with the FHA domain, thus blocking all downstream interactions. To investigate these different FHA binding modes, we solved the crystal structures of the mycobacterial upstream (phosphorylation-dependent) complex PknB-GarA and the downstream (phosphorylation-independent) complex GarA-KGD. Our results show that the phosphorylated activation loop of PknB serves as a docking site to recruit GarA through canonical FHA-pThr interactions. However, the same GarA FHA-binding pocket targets an allosteric site on nonphosphorylated KGD, where a key element of recognition is a phosphomimetic aspartate. Further enzymatic and mutagenesis studies revealed that GarA acted as a dynamic allosteric inhibitor of KGD by preventing crucial motions in KGD that are necessary for catalysis. Our results provide evidence for physiological phosphomimetics, supporting numerous mutagenesis studies using such approaches, and illustrate how evolution can shape a single FHA-binding pocket to specifically interact with multiple phosphorylated and nonphosphorylated protein partners.
INTRODUCTION
Reversible serine-threonine protein phosphorylation mediated by Hanks-type serine-threonine protein kinases (STPKs) and phosphatases has emerged as a major regulatory mechanism in bacteria (1-3). As shown by extensive studies in eukaryotic cells, phosphorylation at serine, threonine, or tyrosine residues can directly alter the biochemical function of a protein, but more often, it creates new docking sites for phosphorylation-dependent binding partners (4) . This supports the idea that phosphorylation-based signal transduction systems can be thought of as tripartite toolkits composed of protein kinases acting as "writers," protein phosphatases as "erasers," and phospho-binding domains as downstream "readers" of the posttranslational modification (5) . Since the discovery of Src homology 2 (SH2) domains (6) , which specifically bind phosphotyrosine residues, many different types of reader domains have been described in eukaryotic cell signaling. The current list of known modules that specifically bind to phosphoserine (pSer) and phosphothreonine (pThr) residues includes no less than 14 unrelated domain types (5) . However, in bacteria, the widespread distribution of STPKs contrasts with the finding that only one of those reader protein modules has so far been found, namely, the Forkhead-associated (FHA) domain (7) .
First identified within the Forkhead family of transcription factors (8) , FHA domains serve as adaptor modules that specifically recognize pThr-containing proteins and mediate protein-protein interactions that are driven by reversible phosphorylation of many eukaryotic regulatory proteins with roles in the DNA damage response, checkpoint signaling pathways, cell growth, and cell cycle regulation (9) . FHA modules share a conserved fold consisting of a 10-or 11-stranded -barrel that contains the pThr-binding pocket at one of the apical surfaces (10, 11) . The atomic structures of more than 50 FHA domains are currently available, and most of these were determined either in the absence of a cognate binding partner or by using a phosphopeptide to represent the binding partner. This strategy is apparently justified by structures in which the target pThr recognized by the FHA lies in an unstructured N-or C-terminal region (12) (13) (14) . Some FHA domains bind nonphosphorylated protein partners using surfaces distinct from the pThr-binding pocket. This may occur in FHA domains that lack the conserved phosphate-interacting residues, such as that of the kinesin KIF13 (15) , or that use their canonical pThr-binding site to interact with a third protein partner, such as the FHA1 domain of Rad51 (16) .
In prokaryotes, FHA domain-containing proteins are ubiquitous in three main phyla, namely, the Actinobacteria, Cyanobacteria, and selected Gram-negative Proteobacteria (7) , but their precise roles in bacterial physiology are generally not well characterized. We focused on GarA, member of an Actinobacterial-restricted family of FHA domain-containing proteins that play a central role in the kinasemediated control of glutamate metabolism (17, 18) . Mycobacterial GarA was initially described as a glycogen accumulation regulator (hence its name) in Mycobacterium smegmatis (19) and identified as an optimal substrate of the serine-threonine protein kinase PknB in Mycobacterium tuberculosis protein extracts (20) . Subsequently, it was characterized as a key regulator of glutamate metabolism in M. tuberculosis, M. smegmatis (13, 18, 21, 22) , and Corynebacterium glutamicum, wherein the GarA ortholog was named OdhI for 2-oxoglutarate dehydrogenase (ODH) inhibitor (23, 24) . GarA is essential to sustain M. tuberculosis growth and viability, but it is dispensable in M. smegmatis and C. glutamicum, in which disruption of garA or odhI, respectively, causes a distinctive, nutrient-dependent phenotype (23, 25) .
GarA protein family members are small proteins (~160 amino acids) consisting of a C-terminal FHA domain linked to an unstructured N-terminal extension of 40 to 50 residues that includes a consensus phosphorylation motif ETTSVFR (Fig. 1A and fig. S1 ). GarA is a key element of a conserved STPK-mediated signaling pathway that controls glutamate metabolism (Fig. 1B) . Nonphosphorylated GarA was shown to activate the glutamate synthase (GS) complex (13) and to inhibit the activities of E1o, the first component of the ODH multiprotein complex, and glutamate dehydrogenase (GDH), a nicotinamide adenine dinucleotide (NAD)-dependent GDH (18) in mycobacteria. Although only the interaction of the GarA homolog OdhI with E1o has been reported in C. glutamicum (23) , the net outcome of the nonphosphorylated OdhI activity is the same as for GarA, namely, a redirection of the metabolic flux toward the synthesis of glutamate (Fig. 1B) . In response to nutrient availability or cell growth requirements (22) , phosphoryl ation at the first or second Thr residue within the ETTSVFR motif by the STPKs PknG or PknB, respectively (Fig. 1B) , triggers the intramolecular association of the N-terminal extension with the C-terminal FHA domain, switching off the modulatory interactions with downstream metabolic enzymes (12, 13, 26) . Therefore, at different stages of the signaling pathway (Fig. 1B) , GarA acts as either a specific STPK protein substrate, a phosphorylation-dependent molecular ON/OFF switch, or an allosteric metabolic modulator. Quite unusually, GarA performs all these tasks using its FHA domain to specifically recognize upstream pThrcontaining proteins (PknB and PknG) and downstream nonphosphorylated protein partners (GS, E1o, and GDH). To gather structural insights into this functional versatility, we report here structural and biochemical studies of the upstream (phosphorylation-dependent) signaling complex PknB-GarA and the downstream (phosphorylationindependent) effector complex GarA-E1o. These studies revealed that the same binding pocket of the GarA FHA domain mediated both docking to the phosphorylated activation loop of PknB through a canonical FHA-pThr interaction and allosteric inhibition of the nonphosphorylated M. smegmatis homolog of E1o through recognition of a phosphomimetic aspartate in the substrate. Together, these observations illustrate how a canonical FHA domainbinding pocket can be fine-tuned to specifically interact with both phosphorylated and nonphosphoryl ated protein partners, extending the functions of prokaryotic FHA domain proteins beyond a simple role of phospho rylation reader domains, with important implications for bacterial cell signaling.
RESULTS
The phospho-dependent signaling complex PknB-GarA In previous work, we showed that M. tuberculosis GarA is an efficient substrate of various STPKs, mainly PknB and PknG (18, 20) . Phosphorylation occurs at Thr 21 (PknG) or Thr 22 (PknB) in the disordered N-terminal extension of GarA, requiring in both cases specific docking interactions between phosphorylated residues in the kinase and the substrate's FHA domain. The autophosphorylated docking sites in PknG are located outside the catalytic domain (18) , but those in PknB (pThr 171 and pThr
173
) are both in the kinase activation loop (20) , and their interaction with the GarA FHA domain would thus be expected to sequester the activation loop away from the active kinase conformation (27) . To address this issue, we sought to characterize the structure of M. tuberculosis GarA in complex with the catalytic domain (residues 1 to 279) of wild-type PknB (hereafter referred to as PknB CD ). The autophosphorylated PknB CD -GarA interaction was observed in solution ( fig. S2 ) with a dissociation constant (K D ) in the micromolar range ( fig. S3 ). Upon extensive crystallization trials, however, all the crystals we obtained contained PknB CD in a "back-to-back" homodimer conformation (28, 29) with no bound GarA. The reported K D for dimerization is high (2.9 mM) (30), suggesting that dimerization of PknB CD in different crystal forms (28) (29) (30) (31) may result from the high protein concentrations used for crystallization. To explore whether kinase dimerization could exclude GarA binding,
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FHA domain we produced a monomeric form of PknB CD by making a point mutation that replaced Leu 33 with glutamic acid (PknB CD,L33E ). The L33E mutation abrogated PknB dimerization (30) but retained wild-type-like phosphorylation activity toward GarA (see the next section). This monomeric form of PknB was successfully crystallized in complex with GarA and the non-hydrolyzable adenosine 5′-triphosphate (ATP) analog AMP-PCP, and the crystal structure of the ternary complex was determined at 2.3 Å resolution (table S1).
E T T S V F R
The crystal structure contained two molecules of the ternary complex in the asymmetric unit and revealed that the FHA domain of GarA interacted primarily with the phosphorylated activation loop of PknB ( Fig. 2A) . Despite using a non-hydrolyzable ATP analog, In (E) and (F), values are the mean of three independent measurements (n = 3), and error bars represent the SEM. Significance of differences between the mean values (E and F) was analyzed statistically (*P < 0.05, Student's t test).
no electron density was visible for the ETTSVFR peptide substrate (GarA residues 20 to 26) in the kinase active site. The entire N-terminal extension of GarA, residues 1 to 45, was mostly disordered in the crystal structure, in agreement with the high flexibility observed for this region in the nuclear magnetic resonance (NMR) structures of nonphosphorylated M. tuberculosis GarA and C. glutamicum OdhI (12, 13) . The only exception was a short peptide fragment (corresponding to GarA residues 26 to 34) that was visible in the electron density map for one of the two independent complexes, between helix G in PknB and a positively charged region of the FHA domain of GarA (Fig. 2, A and B) . This position would be compatible with GarA Thr 22 reaching the kinase active site, because the same peptide fragment occupies a similar position against the FHA domain core in the NMR structures of phosphorylated GarA and OdhI ( fig. S4 , A to C).
A canonical phosphate-binding pocket in the FHA domain
The phosphorylated activation loop, which was systematically disordered in other PknB crystal structures (28) (29) (30) (31) , exhibited an extended conformation at the PknB-GarA interface ( Uniquely among FHA-pThr complexes, however, an additional structural element directly interacts with the phosphorylated residue. The guanidinium group of Arg 58 on PknB helix C made a strong salt bridge with pThr 171 (Fig. 2C ), promoting major structural changes in the helix (see the next section). In addition, the total PknB CD -GarA interface of 1100 Å 2 (including the N-terminal GarA peptide 26-34) was higher than those typically observed for FHA-phosphopeptide complexes. The additional contacts were primarily mediated by the positively charged region formed by the loops 1-2 and 9-10 in the FHA domain of GarA that interact with the C terminus of the PknB activation loop, preceding helix E, and with helix G through the N-terminal GarA peptide (Fig. 2B) .
Upon binding of the GarA FHA domain, the PknB regulatory helix C moved away from the conformation observed in the backto-back PknB homodimer (28) . The helical axis was displaced 6 Å toward the core of the PknB N-lobe, and the helix underwent partial unwinding at its C terminus (Fig. 2D) . As a consequence, the overall conformation of the kinase N-lobe in complex with GarA appears to be incompatible with that observed in the PknB homodimer, possibly accounting for our unsuccessful attempts to crystallize the complex between GarA and wild-type PknB CD . Furthermore, these GarA-induced changes in helix C weaken a well-conserved intramolecular salt bridge in the kinase domain, the integrity of which is usually important for activity because it positions the -and -phosphate groups of ATP correctly for catalysis (32) . This bridge between Lys 40 and Glu 59 from helix C was 4.2 Å in the PknB CD -GarA complex, compared to 2.8 Å in homodimeric PknB CD . Similar conformational changes have been described for two PknB CD point mutants (30) , suggesting a high conformational plasticity of the active kinase.
The kinase activation loop as a docking site for FHA-mediated substrate recruitment To determine the effects of the observed conformational changes on kinase activity, we measured the phosphorylation activity of PknB CD and PknB CD,L33E toward full-length GarA compared to that toward an N-terminal GarA peptide that contained the phosphorylation site but lacked the FHA domain. The activity of the point mutant PknB CD,L33E on each substrate was roughly equivalent to that of wild-type PknB CD on the same substrate (Fig. 2E) , confirming that the amino acid substitution L33E had no major effect on the kinase activity under the assayed conditions. In contrast, the two versions of PknB CD were both markedly less active toward the GarA-derived peptide substrate compared to full-length GarA (Fig. 2E) , indicating that GarA phosphorylation is strongly dependent on the interaction between the kinase activation loop and the FHA domain. An important question here is whether the phosphorylated activation loop is acting as a passive docking platform for substrate recruitment (with no increase of the intrinsic kinase activity) or, alternatively, whether FHA domain binding has an allosteric effect on the kinase activity. To elucidate this issue, we produced a GarA deletion mutant that comprises only the FHA domain but is devoid of the N-terminal phosphorylatable extension, and assayed the kinase activity of PknB CD and PknB CD,L33E on the peptide substrate in the presence or absence of the FHA-only mutant. The addition of FHA failed to increase (it even slightly decreased) the intrinsic kinase activity of PknB CD or PknB CD,L33E toward the peptide substrate (Fig. 2F) , indicating that the FHA domain of GarA does not function as an allosteric kinase activator. Together, the above crystallographic and enzymatic results therefore imply that, in the case of GarA, the phosphorylated activation loop of PknB serves as a docking (phospho)site for substrate recruitment.
The downstream phospho-independent complex GarA-ODH In Actinobacteria, the catalytic domains of components E1o (ODH) and E2o (dihydrolipoamide succinyl transferase) of the ODH complex (homologs of Escherichia coli SucA and SucB, respectively) are encoded in a single polypeptide, named OdhA in Corynebacteriaceae (33) and KGD in Mycobacteriaceae (34) . E1o (SucA) is a thiamin diphosphatedependent enzyme that, in addition to its ODH activity (EC 1.2.4.2) as part of the ODH complex, also exhibits 2-oxoglutarate decarboxylase (EC 4.1.1.71) and 2-oxoglutarate:glyoxylate carboligase (EC 2.2.1.5) activities (21, (34) (35) (36) . In previous work, we characterized the crystal structure of M. smegmatis KGD (21, 37) and demonstrated that GarA inhibited the E1o domain, corresponding to KGD residues 361 to 1227 (KGD 360 ) (21) . To gain insight into the mode of phosphoindependent recognition and inhibition of KGD, we crystallized KGD 360 in complex with the FHA domain of GarA (GarA 44 ) (table S1). M. smegmatis proteins were used, but we maintained M. tuberculosis residue numbering for GarA to allow comparison with the PknB CD -GarA complex [the two mycobacterial GarA homologs are 95% identical (see fig. S1 ), including all residues involved in protein-protein interactions].
The FHA domain of GarA bound to the KGD 360 homodimer with a 2:2 stoichiometry (Fig. 3A) . FHA binding promoted no major conformational changes in KGD 360 , because the overall root mean square deviation (RMSD) between the holo [Protein Data Bank (PDB) code 2YIC] and FHA-bound structures of wild-type KGD 360 was 0.43 Å for 811 C atoms. In addition, the structure of the M. smegmatis FHA domain was structurally identical to that of the PknB-bound M. tuberculosis FHA domain, with an overall RMSD of 0.3 Å for 90 equivalent C atoms. The apical binding surface of the FHA domain was in contact with a strand-connecting loop (residues 586 to 594) and two outer  helices (residues 475 to 500 and 785 to 813) of KGD, ~30 Å away from the catalytic center. The protein-protein interaction buried ~2000 Å 2 of the molecular surfaces and was stabilized through hydrophobic and polar contacts, including several intermolecular salt bridges and hydrogen-bonding interactions (Fig. 3B) of the FHA domain (Fig. 3C) (Fig. 3D) .
The observed GarA-KGD interface is similar to a model proposed for the homologous OdhA-OdhI complex from C. glutamicum (38) and can account for the results of the OdhA-OdhI cross-linking experiments reported in that study. To further validate the observed interface, we produced three KGD surface mutants: (i) substitution of the charged residue Asp 795 that mimics the phosphorylated residue with alanine (D795A); (ii) substitution of two residues involved in the interface, Ser 484 and Ala
488
, with arginine and glutamine, respectively (S484R, A488Q), to prevent formation of a stable complex by adding two bulky side chains; and (iii) substitution of the basic residue Arg 802 , engaged in an intermolecular salt bridge, with alanine (R802A). These mutants retained wild-type decarboxylase activity but differed in their interaction with GarA. Mutants KGD 360,D795A and KGD 360,S484R,A488Q were not inhibited by GarA, even at high concentrations (Fig. 3E) , likely because the mutations precluded FHA binding. These results highlight the functional importance of the phosphomimetic Asp 795 carboxylate and the primary role of the FHA phosphate-binding pocket in phospho-independent KGD recognition. In contrast, KGD 360,R802A was more efficiently inhibited by GarA (Fig. 3E ) than was the wildtype enzyme. The inhibition constant K i was displaced from 2.5 M for wild-type KGD 360 to 0.4 M for KGD 360,R802A . The crystal structure of this KGD point mutant in complex with GarA (table S1) revealed that the absence of the Arg 802 side chain allowed a rotation of 7° of the KGD helix 785-813 with respect to the GarA phosphatebinding pocket, optimizing protein-protein interactions that presumably compensate for the loss of the intermolecular salt bridge. In agreement with this observation, C. glutamicum OdhA has a small side chain (serine) at the equivalent position of KGD Arg 802 and is more efficiently inhibited by OdhI (23), with a K i 100-fold lower than that of GarA for KGD in M. smegmatis.
Dynamic allosteric inhibition of the ODH
GarA binding to a distal region does not block substrate access to the active site, nor does it promote structural changes in KGD. What then is the mode of action of GarA as a KGD inhibitor? Our previous structural and mutagenesis studies of mycobacterial KGD (21, 37) revealed that formation of the post-decarboxylation covalent reaction intermediate triggered important conformational changes, most notably a global rearrangement of the active-site environment that creates a binding funnel for the acceptor substrate(s). These concerted protein motions promote the transition from a basal resting state of KGD to a fully active state (39) and are intimately linked to a ~4 Å shift of a surface-exposed  helix (residues 785 to 813). It is precisely this  helix that lies at the center of the GarA-binding interface and contains the phosphomimetic residue Asp 795 (Fig. 3A) . Therefore, formation of the GarA-KGD complex locks the enzyme in its basal resting state by blocking the helical movement and the ensuing structural transition.
Our structural studies of KGD had shown that formation of the post-decarboxylation covalent intermediate can be achieved in the initial resting conformation, before the structural transition occurs (37) , and therefore should not be affected by GarA binding. To further investigate this hypothesis, we soaked crystals of the KGD 360,R802A -GarA 44 complex for long periods of time in 2-oxoglutarate. The crystal structure, refined at 2.4 Å resolution (table S1), showed no major conformational changes in the active site, indicating that the structural transition had not taken place. However, the post-decarboxylation covalent intermediate derived from 2-oxoglutarate was clearly visible in the electron density maps ( fig. S7 ), demonstrating that GarA binding did not prevent the first reaction step. These results further confirm our proposed inhibition mechanism based on blocking protein motions and are consistent with previous circular dichroism studies of M. tuberculosis KGD, indicating that GarA inhibited the second half of the enzymatic reaction (39) .
Moreover, GarA would be expected to have a differential effect on the reported KGD catalytic activities. By stabilizing the basal conformation of KGD, GarA binding precludes formation of the acceptor substrate-binding sites for the lipoyl and glyoxylate groups needed to complete the dehydrogenase and carboligase reactions, respectively. In contrast, the semialdehyde species in the decarboxylation reaction is generated by direct proton attack to the post-decarboxylation covalent intermediate and should therefore be less affected by GarA.
In agreement with this model, at 5 M concentration, GarA efficiently inhibited the dehydrogenase reaction (no ODH activity could be detected) but did not totally abolish the decarboxylase reaction, because a residual succinic-semialdehyde production (~27% of the value in the absence of GarA) was measured for KGD 360 under the same conditions (40) . Together, the above results demonstrate that nonphosphorylated GarA modulates KGD activity through a dynamic allosteric inhibition mechanism.
Structural basis of FHA-protein interactions
The structures of the phosphorylation-dependent (upstream) and phosphorylation-independent (downstream) GarA complexes described above revealed that, despite the considerable differences in the target proteins, the FHA domain retained its structural integrity and engaged essentially the same molecular surface for protein binding. In the two protein complexes, the interface included the FHA phosphate-binding pocket, defined by the C terminus of strand 3 and the loops 4-5 and 6-7, and a shallow adjacent cleft of positively charged residues from loops 1-2 and 10-11. As shown by NMR studies of the autoinhibited, closed form of GarA (13), this same interface was also used for self-recognition of pThr 22 (Fig. 4, A to C) . The dual binding specificity of GarA toward phosphorylated and nonphosphorylated proteins is intriguing. Guided by the available structures, we performed surface plasmon resonance (SPR) experiments to explore the effect of four M. smegmatis GarA mutations within the common interface: one involving a central pThr-binding residue, Ser 95 (S95A), and three others involving positively charged residues from the adjacent region, Arg (18, 20) . However, the same GarA substitution, S95A, had no effect on the KGD dissociation constant (Table 1 and fig. S8B ). This last result is consistent with a previous observation that this mutation does not affect KGD inhibition (13) but seems to contradict the essentiality of phosphomimetic KGD Asp 795 (Fig. 3, C and E) . This apparent discrepancy is probably due to a distinct pattern of interactions involving the Asp 795 carboxylate (compared to a pThr residue) in the phosphate-binding pocket. The carboxylate group is hydrogen-bonded to the hydroxyl group of Ser 95 and to a water molecule, which, in turn, makes strong hydrogen bonds with Asn 117 and main-chain backbone atoms of GarA (Fig. 3C ). Because it disrupts the whole hydrogen-bonding network, the substitution of KGD Asp 795 (D795A) is therefore expected to have a stronger effect on the binding energy than that of GarA Ser 95 (S95A). In addition to the dissimilarities in the phosphate-binding pocket (occupation by pThr versus Asp), the PknB CD -GarA and GarA-KGD complexes also differ in the interactions on the positively charged face of the FHA domain: substitutions of the GarA basic residues R62A, K141E, or R143A in the loops 1-2 and 10-11 had little or no effect on the PknB CD binding affinity (Table 1 and fig. S8A ). In contrast, these same substitutions were found to considerably affect KGD binding (Table 1) , because the basic residues make several ionic interactions with the KGD loop 586-594 (Fig. 3D) . In summary, the above observations suggest that recognition of KGD is driven by extensive interactions, not only with the phosphate-binding pocket but also with the adjacent basic cleft of GarA, which are required to efficiently block KGD protein motions during catalysis, whereas recognition of autophosphorylated PknB [or the GarA N-terminal phosphopeptide in the autoinhibited closed form (12, 13) ] is dominated by interactions of the pThr residue with the canonical phosphatebinding pocket of GarA.
DISCUSSION
FHA domains are the only type of eukaryotic-like phosphoresiduebinding protein modules so far identified in bacteria, where they fulfill important albeit poorly characterized roles. For instance, in M. tuberculosis, at least five FHA domain-containing proteins have been reported to participate in the STPK-mediated control of essential biological processes such as cell wall synthesis (14, 41) , cell division (42) , and central metabolism (18) . In particular, the GarA-mediated control of a crucial node at the crossroads of carbon and nitrogen metabolism, conserved in and restricted to Actinobacteria (Fig. 1B) , arguably represents the bacterial FHA domain-mediated signaling pathway with the most complete molecular description so far. Together with previous studies on mycobacterial GarA and corynebacterial OdhI (13, 18, 19, (22) (23) (24) (25) , our results substantially broaden the known functional versatility of the FHA domain beyond that of a simple pThr-recognition module in cell signaling. In particular, the structures of the upstream and downstream GarA complexes demonstrate how a single FHA domain protein can engage its canonical phosphate-binding pocket in biologically relevant, specific, phosphorylation-dependent as well as phosphorylation-independent, protein-protein interactions (Fig. 4) . Moreover, the same binding region of the FHA domain is likely involved in the interaction of GarA with at least two other metabolic, structurally unrelated enzymes, because the amino acid substitutions S95A in the phosphate-binding pocket and K141E in the adjacent basic region abolish GarA binding and regulation of glutamate synthase and NAD-dependent GDH in mycobacteria (13) .
This dual binding specificity of the GarA FHA domain can be partially accounted for by phosphate mimicry of KGD Asp 795 , which is crucial for complex formation and occupies the phosphate-binding pocket. Aspartate and glutamate are frequently used as "phosphomimetic" fig. S8 ) of three or more independent experiments. n.d., not determined (no reliable fit). residues to probe the constitutively phosphorylated state in protein phosphoregulation studies and even for structural studies (43, 44) . Although in some cases it has been suggested that phosphomimetic mutations might enhance FHA binding (45) (46) (47) , there had been no previous structural evidence for this, and extensive published studies have instead suggested that phosphomimetic residues might not fit into the binding site of FHA domains or other adaptor proteins [reviewed in (48) and references therein]. Here, the structure of the GarA-KGD complex illustrates a clear example of functional, naturally occurring phosphomimetics. The carboxylate group of KGD Asp 795 , a residue essential for complex formation with GarA, occupies a similar position as the pThr side chain in the PknB-GarA complex, with a water molecule filling the cavity left by the missing oxygen atoms of the phosphate to partially restore the hydrogen-bonding network (Fig. 3C ). These observations demonstrate that phosphomimetic recognition by FHA domains is possible, although in this case we should emphasize that it is favored by additional protein-protein interactions outside the phosphate-binding pocket.
In addition to contributing to a better understanding of the GarAmediated signaling pathway at the molecular level, the individual crystal structures reported here raise important mechanistic issues. For example, the role of protein dynamics in enzyme function remains poorly understood or difficult to interpret (49) . Previously published crystal structures of KGD (21, 37) stressed the importance of protein motions for efficient catalysis and regulation, and that of the GarA-KGD complex now illustrates a potential approach for using dynamics to modulate function (50) and eventually to design efficient enzyme inhibitors. On the other hand, the structure of the PknB-GarA complex raises puzzling questions on the kinase activation mechanism. Phosphorylation of the activation loop is a hallmark of the active state for many serine-threonine protein kinases (32, 51) , because it usually leads to conformational changes required for catalysis (52) . In PknB, phosphorylation of two Thr residues in the activation loop is also required for full kinase activity (53) , but the structural and activity studies reported above suggest that the interaction between the pThr residues and the HRD motif is not required to achieve a catalytically competent active site. Instead, it appears that phosphorylation of the activation loop serves to generate a docking site for FHA domain-mediated GarA recruitment, which accounts for the high kinase activity toward this particular substrate. Further experiments are required to elucidate the molecular mechanisms underpinning kinase activation against other PknB substrates.
In summary, the work reported here revealed structural snapshots of a single FHA domain protein caught in upstream and downstream protein-protein complexes, providing important insights not only into the functional adaptability of these domains in bacterial signaling but also into kinase activation and unanticipated allosteric dynamic mechanisms of metabolic regulation.
MATERIALS AND METHODS
Reagents
The synthetic 17-mer peptide SDEVTVETTSVFRADFL, corresponding to residues 14 to 30 of M. tuberculosis GarA (MtGarA), was purchased from Thermo Fisher Scientific (purity, >98%).
Cloning and mutagenesis
Genes were amplified by polymerase chain reaction from genomic DNA of M. smegmatis mc 2 155 (MSMEG_5049 for kgd, MSMEG_3647
for garA, MSMEG_4283 for dlaT, and MSMEG_0903 for lpdA) and M. tuberculosis H37Rv (Rv0014c for pknB, Rv0243c for gabD1, and Rv1827 for garA) and cloned into pET-28a (Novagen) or pDEST17 (Invitrogen), as previously described (21, 26, 28) . Site-directed mutagenesis was performed on pET28a-MtPknB CD (L33E), pET28a-MsKGD 360 (R802A, D795A, S484R/A488Q), and pET28a-MsGarA (R62A, S95A, K141E, R143A). All plasmids were verified by DNA sequencing.
Protein production
The recombinant proteins MsKGD, MsKGD 360 , MsGarA, MsDlaT, MsLpd, MtGabD1, and MtGarA and the two FHA domains alone (MsGarA 44 used in cocrystallization with KGD 360 and MtGarA 43 used for kinase assays) were overproduced in E. coli and purified as previously described (21, 26) . MsGarA and its mutant versions were also produced in microfermentor units, following established protocols (54) . MtPknB 1-279 (referred to as PknB CD ) and its mutant version carrying the substitution L33E (PknB CD,L33E ) were expressed for 15 hours at 22°C with 100 M isopropyl--d-thiogalactopyranoside (IPTG). Both proteins were purified using the same protocol. E. coli cells were harvested by centrifugation, resuspended in lysis buffer [50 mM NaH 2 PO 4 (pH 8), 500 mM NaCl, 5% glycerol, 25 mM imidazole, and 1 mM dithiothreitol (DTT)] supplemented with cOmplete protease inhibitor cocktail (Roche) and sonicated. After centrifugation, the supernatant was loaded onto a 5-ml HisTrap HP column (GE Healthcare), and the His-tagged protein was purified by applying a linear imidazole gradient (25 to 500 mM). Next, the His 6 tag was removed by incubating for 18 hours at 18°C in the presence of His 6 -tagged Tobacco Etch Virus (TEV) protease (55) at a 1:30 ratio (w/w) in buffer [25 mM Hepes (pH 8), 150 mM NaCl, 5% glycerol, and 1 mM DTT] followed by separation on a Ni-nitrilotriacetic acid (NTA) agarose column (Qiagen). Then, the protein was further purified by size exclusion chromatography on a Superdex 200 column (GE Healthcare) equilibrated in 25 mM Hepes (pH 8), 150 mM NaCl, 5% glycerol, and 1 mM DTT. Fractions corresponding to the PknB peaks, as confirmed by SDS-polyacrylamide gel electrophoresis, were later pooled and concentrated up to 40 mg/ml, flash-frozen in liquid nitrogen, and stored at −80°C. All proteins were quantified using the molar absorption coefficient predicted from the amino acid sequence by the ProtParam tool (http://web.expasy.org/protparam/). Fig. 2F were done in the absence or presence of 92 M MtGarA 43 . The enzyme concentration in the assays was 0.2 to 5 M and 3 to 12 nM when using the 17-mer peptide or MtGarA as substrates, respectively. The kinase reactions were started by the addition of 4 l [-
Enzyme activity assays
32 P]ATPMn +2 and were performed at room temperature. The reactions were stopped by the addition of phosphoric acid, and 4 l of each reaction was spotted on P81 phosphocellulose papers (Whatman) using the epMotion 5070 (Eppendorf) workstation. The papers were washed in 0.01% phosphoric acid, dried, and then measured and analyzed using a PhosphorImager (FLA-9000 Starion, Fujifilm). Each reaction was performed in duplicate (<10% variation), and each assay was performed at least twice (<20% variation). In all cases, specific activity values were derived from reactions performed using three different enzyme concentrations within the indicated ranges (<20% variation), verifying a linear dependence of activity with kinase concentration. The proportion of 17-mer peptide or MtGarA consumed in the reactions was lower than 10% and 30%, respectively. MtGarA consumption was verified to be linear in time up to 50% its initial concentration. Under the experimental conditions used to test phosphorylation of the 17-mer peptide or MtGarA, PknB CD or PknB CD,L33E autophosphorylation represented less than 5% of the total signal. The measured signal was at least five times higher than the lecture on the background.
Determinations of 2-oxoglutarate decarboxylase and ODH activities were carried out as previously described (21) . Briefly, for the decarboxylase activity, reactions contained 2 M MsKGD 360 , 1 to 3 mM 2-oxoglutarate, 0.2 mM ThDP, 1 mM MgCl 2 , 0.55 to 1.1 M MtGabD1, and 1 to 2 mM NADP + (nicotinamide adenine dinucleotide phosphate) in 50 mM potassium phosphate (pH 6.5). Reactions were started by the addition of 2-oxoglutarate at 37°C, and initial rates were calculated during the linear phase of the reaction (10 to 20 min) following 340-nm absorbance using a microplate reader. For measuring ODH activity, the reaction contained 1 to 3 mM 2-oxoglutarate, 1 mM CoA-SH, 0.2 mM ThDP, 1 mM MgCl 2 , 2 M MsKGD, 4 M MsDlaT, 0.5 M MsLpd, and 1 to 2 mM 3-acetylpyridine dinucleotide (AcNAD + ) in 50 mM potassium phosphate (pH 6.5). AcNAD ). When appropriate, MsGarA was diluted in PBS and added to the assay mixture at 5 M, unless otherwise stated. Experiments were performed in triplicate.
Isothermal titration calorimetry
MtGarA binding to PknB CD or PknB CD,L33E was assayed using a high-precision VP-ITC system (MicroCal Inc.) with the following parameters: the isothermal titration calorimetry (ITC) cell (1.4 ml) contained 10 M MtPknB, preincubated with 2 M ATP in 25 mM Hepes (pH 7.5), 150 mM NaCl, and 1 mM DTT, and the syringe (150 l) contained 250 M MtGarA in the same buffer. Sample solutions were thoroughly degassed under vacuum, and each titration was performed at 15°C by injections of 10 l every 210 s using a 290 rpm rotating syringe. Raw heat signal collected with a 16-s filter was corrected for the dilution heat and normalized to the concentration of ligand injected. Data were fit to a bimolecular model using the Origin software provided by the manufacturer. The ITC experiments were performed at least twice to ensure reproducibility. A representative experiment is shown in fig. S3 , from which the reported thermodynamic parameters have been calculated.
Analytical ultracentrifugation
Sedimentation coefficients were determined at 20°C, using a Beckman Coulter XL-I centrifuge equipped with an AN60-Ti rotor equipped with Rayleigh interference detection. Samples were centrifuged for 17 hours at 42,000 rpm, and profiles were recorded every 5 min. Sedimentation scans were analyzed by the continuous size distribution procedure c(S) with the program Sedfit 15.01 (56) . All c(S) distributions were calculated with a fitted frictional ratio f/f0 and a maximum entropy regularization procedure with a confidence level of 0.68. Theoretical sedimentation coefficients were calculated from the atomic coordinates using HYDROPRO (57) and compared to the experimental sedimentation coefficients obtained from ultracentrifugation analysis.
Surface plasmon resonance SPR measurements were performed at 25°C on an NTA sensor chip using a Biacore 2000 instrument (GE Healthcare) equilibrated with 25 mM Hepes (pH 8), 150 mM NaCl, 50 M EDTA, and 0.005% Tween 20 (running buffer). The sensor chip was activated by injecting 0.5 mM NiCl 2 followed by the capture of the His-tagged proteins MsKGD full length and MtPknB CD on two independent channels. The reference flow cell was prepared by the same procedure in absence of protein. Various concentrations of wild-type MsGarA, or the singlepoint mutants R61A, S94A, K140E, and R142A (referred to in the text as R62A, S95A, K141E, and R143A, respectively, to maintain consistency with MtGarA residue numbering), were injected onto the surfaces at a flow rate of 50 l min −1 , and the binding signals were monitored. Protein dissociation was realized by injecting the running buffer, and the surface was regenerated by injecting 0.25 M imidazole followed by 0.35 M EDTA and 0.1% SDS before the next cycle. Control flow cell sensorgrams were subtracted from the ligand flow cell sensorgrams, and averaged buffer injections were subtracted from analyte sensorgrams. Response at equilibrium (Req) was obtained directly from the plateau region of the sensorgrams. The saturation curves obtained by plotting Req versus the analyte concentration were fitted with a steady-state model to obtain the apparent equilibrium dissociation constant K D , using the BIAevaluation 4.2 software (GE Healthcare).
Crystallization and data collection
Crystallization screenings were carried out using the sitting-drop vapor diffusion method and a Mosquito nanoliter-dispensing crystallization robot (TTP Labtech); hits were improved by handmade hanging drops in 24-well plates at the same temperature. Optimized conditions for crystal growth of the different protein complexes (protein concentrations of 20 to 25 mg/ml, molar ratio of 1:1) are as follows: (i) MtPknB L33E -MtGarA: 100 mM Hepes, 4% (w/v) PEG400 (polyethylene glycol, molecular weight 400), 2 M (NH 4 ) 2 SO 4 , and 4 mM AMP-PCP (pH 7.5); (ii) MsKGD 360 -MsGarA 44 : 50% 2-methyl-2,4-pentanediol (MPD), 100 mM MES, 2 mM ThDP, and 5 mM MgCl 2 (pH 6.5); and (iii) MsKGD 360,R802A -MsGarA 44 : 47% MPD, 100 mM Na Hepes, 2 mM ThDP, and 5 mM MgCl 2 (pH 7.5). The enamine-ThDP reaction intermediate for KGD in the presence of GarA was obtained by soaking crystals of the MsKGD 360,R802A -MsGarA 44 (grown as described above) with 20 mM 2-oxoglutarate for 8 min before freezing.
X-ray diffraction data were collected from single crystals at 100 K using synchrotron radiation at beamlines Proxima 1 (Synchrotron Soleil, Saint-Aubin, France) and ID14-1 (ESRF, Grenoble, France). Data processing was carried out with programs XDS (58) and AIMLESS (59) .
Structure determination and refinement
The crystal structures of all protein complexes were solved by molecular replacement techniques using either the MtPknB catalytic domain (PDB code 1O6Y) or the apo form of MsKGD 360 (PDB code 2YIC) as search probes with the program PHASER (60) . The bound FHA domain in all structures, as well as the cofactor ThDP (for the KGD complexes) or the nucleotide AMP-PCP (for the PknB complex), was clearly visible in Fourier difference maps and could be manually traced during refinement. All crystallographic models were refined through iterative cycles of manual model building with COOT (61) and reciprocal space refinement with BUSTER (62) . Because of important conformational changes in the PknB kinase core, the entire N-lobe was removed during the first refinement rounds and gradually rebuilt through iterative cycles of refinement and manual model building. The structure was validated through the MolProbity server (http://molprobity.biochem.duke.edu). Figures were generated and rendered with PyMOL 1.5.0.2 (Schrödinger LLC).
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